山东医药2012，Vol.52Issue(25)：16-18,3.
便秘型肠易激综合征的SERT基因多态性及其与患者临床疗效的关系
Sertotonin-transporter polymorphism in constipation-predominanti irritable bowel syndrome and its influence on clinical effect of tegaserod
摘要
Abstract
Objective To investigate the potential association between the serotonin reuptake transporter(SERT) polymorphisms and the constipation predominant irritable bowel syndrome (C-IBS) phenotype, also to investigate the impact of SERT genotypes on the efficacy of 5-HT4 receptor agonist tegaserod in constipation predominant type patients. Methods PCR was used to detect the 5-HTTLPR and VNTRs polymorphisms of SERT gene in 84 patients with C-IBS confirmed with Rome HI criteria and 103 healthy subjects, then 61 C-IBS patients received tegaserod 6 mg twice daily for 4 weeks. Patients recorded their symptoms in a diary. Efficacy was assessed by patient' s overall symptoms of IBS and severity of constipation before and after tegaserod treatment. Results There was significant difference between patients and controls on genotypes of the 5-HTTLPR gene (P < 0. 01) , and the allele frequencies of the 5-HTTLPR allele L/L genotype was significantly higher in the constipation predominant IBS (C-IBS) group than in the controls (25% vs 7. 8% , P < 0. 05 ). The clinical responder rates of tegaserod in S/S and S/L genotypes significantly differed from those in L/L genotype ( S/S 93. 1% , S/L 70. 6% , L/L 33. 3% , P <0.01). Conclusions The 5-HTTLPR polymorphisms of SERT gene were probably associated with C-IBS. SERT gene polymorphisms influenced the efficacy of tegaserod in C-IBS patients.关键词
肠易激综合征/多态性/单核苷酸/替加色罗Key words
irritable bowel syndrome/ polymorphisms, single nucleotide/ tegaserod分类
医药卫生引用本文复制引用
张自翔,谢军,黄才斌,廖跃光,舒涛,付曲波..便秘型肠易激综合征的SERT基因多态性及其与患者临床疗效的关系[J].山东医药,2012,52(25):16-18,3.基金项目
江西省自然科学基金项目(2008GZY0073) （2008GZY0073）
江西省卫生厅科技计划项目(20063157). （20063157）
